Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 48

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 48
---
| · | the potential for bacteriophage technology being                           
 uniquely positioned to address the global threat of antibiotic resistance; |

| · | our planned development strategy, presenting                       
 data to regulatory agencies and defining planned clinical studies; |

| · | the expected timing of additional clinical trials,            
 including Phase 1b/Phase 2 or registrational clinical trials; |

| · | our ability to manufacture and secure sufficient          
 quantities of our product candidates for clinical trials; |

| · | the drug product candidates to be supplied by 
 us for clinical trials;                       |

| · | the safety and efficacy of our product candidates; |

| · | our anticipated regulatory pathways for our product 
 candidates;                                         |

| · | the activities to be performed by specific parties 
 in connection with clinical trials;                |

| · | our ability to successfully complete preclinical                                                                                              
 and clinical development of, and obtain regulatory approval of our product candidates and commercialize any approved products on our expected 
 timeframes or at all;                                                                                                                         |

| · | our pursuit of additional indications; |

| · | the content and timing of submissions to and             
 decisions made by the FDA and other regulatory agencies; |

| · | our ability to leverage the experience of our                                 
 management team and to attract and retain management and other key personnel; |

| · | the capacities and performance of our suppliers,                                                          
 manufacturers, contract research organizations and other third parties over whom we have limited control; |

| · | our ability to staff and maintain our Los Angeles 
 production facility under fully compliant cGMP;   |

| · | the actions of our competitors and success of                        
 competing drugs or other therapies that are or may become available; |

| · | our expectations with respect to future growth                                                
 and investments in our infrastructure, and our ability to effectively manage any such growth; |

| · | the size and potential growth of the markets                                                                
 for any of our product candidates, and our ability to capture share in or impact the size of those markets; |

| · | the benefits of our product candidates; |

| · | the potential market growth and market and industry 
 trends;                                             |

| · | maintaining collaborations with third parties        
 including our partnerships with the CFF and the DoD; |

| · | potential future collaborations with third parties                         
 and the potential markets and market opportunities for product candidates; |

<div align='center'>11</div>

| · | our ability to achieve our vision, including                     
 improvements through engineering and success of clinical trials; |

| ·